Tesamorelin vs Ipamorelin: How They Differ and the Evidence
Tesamorelin vs ipamorelin comes down to two receptors and two records: the Egrifta SV FDA label says tesamorelin acts on the GHRH receptor, while a 2009 paper (PMID 19289567) describes ipamorelin as a ghrelin receptor agonist. Tesamorelin is sold as Egrifta SV. Its use is to cut extra belly fat in adults with HIV and lipodystrophy. Ipamorelin acts on the ghrelin receptor instead. We found no FDA label for it. In a phase 2 trial after bowel surgery, it did no better than placebo.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Animal study (rodents): Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, June 2009. PMID 19289567. Supports: ipamorelin as a selective growth hormone secretagogue and ghrelin receptor agonist; Randomized trial (phase 2): Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PMID 25331030. Supports: phase 2 design; no significant difference from placebo; 0.03 mg/kg twice daily up to 7 days well tolerated
Short answer
- Do they work the same way?
- No. Tesamorelin works on the GHRH receptor. Ipamorelin works on the ghrelin receptor. Both lead to growth hormone release.
- Which one is approved?
- Tesamorelin is, as the prescription drug Egrifta SV. It has one narrow use. We found no FDA label for ipamorelin.
- How long do they last in the body?
- The tesamorelin label reports a mean half-life of 8 minutes. A 1999 volunteer study reports a half-life of 2 hours for ipamorelin.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Animal study (rodents): Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, June 2009. PMID 19289567. Supports: ipamorelin as a selective growth hormone secretagogue and ghrelin receptor agonist; Human study (healthy volunteers): Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, September 1999. PMID 10496658. Supports: GH release at all dose levels; dose-proportional levels; 2 hour half-life
Tesamorelin vs Ipamorelin Side by Side
Tesamorelin and ipamorelin both raise growth hormone, but only tesamorelin has an FDA label (Egrifta SV), and no study has compared the two head to head. This table puts the label and study facts side by side.
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| What it is | A copy of the body signal that tells it to make growth hormone (a GHRF analog) | A drug that makes the body release growth hormone (a secretagogue) |
| Receptor | Human GRF receptor, also called the GHRH receptor | The ghrelin receptor |
| FDA label | Yes: Egrifta SV | None found in openFDA |
| Labeled use | Excess belly fat in adults with HIV and lipodystrophy | None |
| Prescription | Yes: a prescription shot | No approved product to prescribe |
| Half-life | 8 minutes (label, healthy subjects) | 2 hours (1999 volunteer study) |
| Main human data | The data summarized in its FDA label | A volunteer study and a phase 2 bowel surgery trial |
| Phase 2 result | Not part of our sources | No clear difference from placebo |
No study has compared the two head to head in people. The table compares records, not results from one trial. For research on using them together, see our tesamorelin and ipamorelin blend guide.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Animal study (rodents): Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, June 2009. PMID 19289567. Supports: ipamorelin as a selective growth hormone secretagogue and ghrelin receptor agonist; Human study (healthy volunteers): Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, September 1999. PMID 10496658. Supports: GH release at all dose levels; dose-proportional levels; 2 hour half-life; Randomized trial (phase 2): Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PMID 25331030. Supports: phase 2 design; no significant difference from placebo; 0.03 mg/kg twice daily up to 7 days well tolerated
Do Tesamorelin and Ipamorelin Work the Same Way?
No. Tesamorelin works on the GHRH receptor, per the Egrifta SV FDA label, and ipamorelin works on the ghrelin receptor, per a 2009 paper in the Journal of Pharmacology and Experimental Therapeutics. They push the same hormone through two separate doors.
Tesamorelin: a copy of the body's own signal
The Egrifta SV label calls tesamorelin a GHRF analog. GHRF stands for growth hormone-releasing factor. It is also called GHRH. It is the body's own signal to make growth hormone. An analog is a lab-made copy. In lab tests, the label says, tesamorelin binds and turns on human GRF receptors. It does this about as strongly as the body's own GRF.
Ipamorelin: a ghrelin mimic
A 2009 paper calls ipamorelin a selective growth hormone secretagogue. A secretagogue makes a gland release something, here growth hormone. The paper also calls it an agonist of the ghrelin receptor. An agonist is something that switches a receptor on.
Because the receptors differ, results for one do not carry over to the other. Take tesamorelin's effect on belly fat in people with HIV. That finding says nothing direct about ipamorelin. For a related comparison on the GHRH side, see tesamorelin vs sermorelin.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Animal study (rodents): Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, June 2009. PMID 19289567. Supports: ipamorelin as a selective growth hormone secretagogue and ghrelin receptor agonist
Do You Need a Prescription for Tesamorelin?
Yes. The Egrifta SV FDA label calls tesamorelin an injectable prescription medicine, while ipamorelin has no FDA label we could find in openFDA. So for ipamorelin there is no approved product to prescribe.
The approved use for tesamorelin is narrow. The label says Egrifta SV is for cutting extra belly fat. It is for adults with HIV who have lipodystrophy, a change in where the body stores fat. The label also says it is not for weight loss, because it has a weight neutral effect.
Ipamorelin is different. We found no FDA label for it in openFDA. The FDA lists ipamorelin acetate on a page of raw ingredients. These are ones that may carry serious safety risks when pharmacies mix drugs.
A 2026 review looked at peptides that act on growth hormone. It says none is approved for body shape or sports performance. It also says, outside regulated supply, no one can be sure what is in a product. The dose and how people stack products are unclear too.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the ipamorelin acetate entry (immune reaction risk; serious adverse events including death when given by vein for gastric motility); Review: Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Frontiers in Endocrinology, 2026. PMID 42395176. Supports: no regulatory approval for physique or performance uses; uncertain product makeup, dose and stacking
What the Tesamorelin Label Shows
The Egrifta SV FDA label (DailyMed, version dated 29 July 2026) gives tesamorelin's use, dose, half-life of 8 minutes, side effects and warnings. Ipamorelin has nothing like that.
The Egrifta SV label gives a half-life of 8 minutes on average. That was in healthy people after one shot under the skin. Half-life is the time it takes for half the drug to leave the blood. So tesamorelin clears fast.
The label also has a warning. The Egrifta SV label says tesamorelin boosts growth hormone and raises IGF-1 in the blood. IGF-1 is a growth factor. The effects of high IGF-1 over a long time are unknown. The label says to check IGF-1 during treatment. More on the tesamorelin profile.
What the Ipamorelin Studies Show
Ipamorelin's human data are a 1999 volunteer study in Pharmaceutical Research (PMID 10496658) and a 2014 phase 2 bowel surgery trial (PMID 25331030) that found no significant difference from placebo. Neither tested fat or muscle.
The 1999 volunteer study
This study was in healthy volunteers. It looked at how the body handles ipamorelin and how much growth hormone it releases. Ipamorelin released growth hormone at every dose level. A bigger dose gave higher blood levels, in step. The half-life was short, at 2 hours (PMID 10496658).
The 2014 bowel surgery trial
This was a phase 2 randomized trial. It tested ipamorelin for postoperative ileus. That is when the bowel is slow to start working again after surgery. The patients had part of the bowel removed (bowel resection). Ipamorelin did no better than placebo. That held for the main results and the other results.
The trial said people handled the study dose well. The dose is shown in the dose section below. More on the ipamorelin profile and in sermorelin vs ipamorelin.
Sources: Human study (healthy volunteers): Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, September 1999. PMID 10496658. Supports: GH release at all dose levels; dose-proportional levels; 2 hour half-life; Randomized trial (phase 2): Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PMID 25331030. Supports: phase 2 design; no significant difference from placebo; 0.03 mg/kg twice daily up to 7 days well tolerated
How Quickly Do You See Results From Ipamorelin?
No human study gives a timeline for visible results from ipamorelin; the only timing data, from a 1999 volunteer study (PMID 10496658), are a growth hormone rise and a 2 hour half-life. Neither is a change you can see.
The 1999 study found growth hormone was released at every dose level. The half-life was 2 hours. A hormone rise is not the same as a change in fat, muscle or recovery. No trial we found measured those things for ipamorelin. For tesamorelin, the label covers cutting extra belly fat in its approved group. But our sources do not give a week-by-week timeline.
Sources: Human study (healthy volunteers): Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, September 1999. PMID 10496658. Supports: GH release at all dose levels; dose-proportional levels; 2 hour half-life; FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine)
Side Effects and Safety
The Egrifta SV label lists tesamorelin's most common side effects as allergic reactions, fluid-related problems, high blood sugar and injection site reactions. For ipamorelin, the FDA warns of immune reaction risk and notes a published report of serious adverse events, including death, when given by vein.
Tesamorelin, from the label
The most commonly reported adverse reactions were:
- Allergic reactions (hypersensitivity), such as rash and hives
- Fluid-related problems (edema), such as joint pain, arm or leg pain, swelling and carpal tunnel syndrome
- High blood sugar
- Reactions where the shot goes in
Ipamorelin, from the FDA and the trial
The FDA says pharmacy-made (compounded) ipamorelin acetate may cause immune reactions for some routes. The reasons are clumping (aggregation) and impurities. The FDA also points to a published study. In it, ipamorelin was given by vein to get the stomach moving (gastric motility). The study found serious side effects, including death.
The FDA note on serious side effects, including death, is about ipamorelin given into a vein to get the stomach moving. It comes from a published study. It is a safety warning sign. The FDA page does not give more detail.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the ipamorelin acetate entry (immune reaction risk; serious adverse events including death when given by vein for gastric motility)
Label and Trial Doses
Only tesamorelin has a labeled dose, 1.4 mg once daily under the skin per the Egrifta SV FDA label. The ipamorelin figure comes from one bowel surgery trial (PMID 25331030) and is not an approved dose.
The FDA label for Egrifta SV lists:
Egrifta SV: 1.4 mg (0.35 mL of the reconstituted solution) injected under the skin once daily
Disclaimer: this is label information for the approved use. It is not a recommendation. Dose decisions belong with a licensed clinician.
The 2014 phase 2 bowel surgery trial reported:
Ipamorelin: 0.03 mg/kg twice daily for up to 7 days (trial dose, well tolerated)
Disclaimer: this is a trial dose in patients after bowel surgery. It is not label information and not a recommendation. That trial found no clear benefit over placebo. Dose decisions belong with a licensed clinician.
For the unit math behind the tesamorelin label dose, the tesamorelin calculator shows the arithmetic only.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Randomized trial (phase 2): Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PMID 25331030. Supports: phase 2 design; no significant difference from placebo; 0.03 mg/kg twice daily up to 7 days well tolerated
Common Questions
Do tesamorelin and Ipamorelin work the same way?+
No. Both lead to growth hormone release, but through different receptors. The Egrifta SV label says tesamorelin binds and turns on the GRF receptor, also called GHRH. Ipamorelin switches on the ghrelin receptor instead.
Do you need a prescription for tesamorelin?+
Yes, for the approved product. The Egrifta SV label calls it an injectable prescription medicine. Its label use is to cut extra belly fat in adults with HIV who have lipodystrophy.
Is ipamorelin FDA approved?+
We found no FDA label for ipamorelin in openFDA. The FDA lists ipamorelin acetate on a page of raw ingredients. They may be risky when pharmacies mix drugs (compounding). It warns of possible immune reactions for some routes.
How quickly do you see results from Ipamorelin?+
No human study gives a timeline for body changes. A 1999 study in healthy volunteers found ipamorelin released growth hormone at every dose tested. Its half-life was 2 hours. That measures a hormone response, not a visible result.
Is tesamorelin used for weight loss?+
No. The Egrifta SV label says it is not for weight loss. The reason it gives is that the drug has a weight neutral effect. Its label use is cutting extra belly fat in adults with HIV and lipodystrophy.
Which has more human evidence, tesamorelin or ipamorelin?+
Tesamorelin. It has an FDA label. Ipamorelin has a volunteer study and one phase 2 trial after bowel surgery. That trial found no clear difference from placebo.
What are the side effects of tesamorelin?+
The Egrifta SV label lists the most common ones. They are allergic reactions such as rash, and fluid-related problems such as joint pain and carpal tunnel syndrome. High blood sugar and reactions where the shot goes in are also listed. The label warns that tesamorelin raises IGF-1. The effects of high IGF-1 over a long time are unknown.
Sources: FDA label: EGRIFTA SV (tesamorelin for injection) FDA prescribing information, DailyMed set ID 3d783378-b02d-4f19-99dd-0fc91a042224 (version dated 29 July 2026, retrieved October 2026). Sections used: Indications and Usage (use; not for weight loss), Dosage and Administration (1.4 mg once daily), Warnings and Precautions (IGF-1), Adverse Reactions, Clinical Pharmacology 12.2 (GRF receptor) and pharmacokinetics (8 minute half-life), and the patient information (prescription medicine); Animal study (rodents): Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, June 2009. PMID 19289567. Supports: ipamorelin as a selective growth hormone secretagogue and ghrelin receptor agonist; Human study (healthy volunteers): Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, September 1999. PMID 10496658. Supports: GH release at all dose levels; dose-proportional levels; 2 hour half-life; Randomized trial (phase 2): Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, December 2014. PMID 25331030. Supports: phase 2 design; no significant difference from placebo; 0.03 mg/kg twice daily up to 7 days well tolerated; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the ipamorelin acetate entry (immune reaction risk; serious adverse events including death when given by vein for gastric motility)
Related reading
Tesamorelin Ipamorelin Blend
Research on the two used together
Tesamorelin
Full profile of the labeled GHRH analog
Ipamorelin
Full profile of the ghrelin receptor agonist
Tesamorelin vs Sermorelin
Two GHRH analogs compared
Sermorelin vs Ipamorelin
GHRH analog vs ghrelin mimic
HGH vs Peptides
Growth hormone and the peptides said to act on it
This guide is for educational purposes only and is not medical advice. It describes what the Egrifta SV FDA label, published studies and the FDA report about tesamorelin and ipamorelin. It is not an endorsement or an instruction to use any compound. Ipamorelin is not an FDA-approved medicine. Talk to a qualified healthcare professional before making any decision about your health.